Drug Profile


Alternative Names: Donesta; E4

Latest Information Update: 14 Mar 2017

Price : $50

At a glance

  • Originator Pantarhei Bioscience
  • Class Gonadal steroid hormones; Hormonal replacements; Oral contraceptives; Small molecules
  • Mechanism of Action Estrogen receptor beta modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atrophic vaginitis; Breast cancer; Osteoarthritis; Pregnancy; Vasomotor symptoms
  • Phase I Migraine; Prostate cancer
  • Discontinued Cardiovascular disorders; Multiple sclerosis; Sjogren's syndrome

Most Recent Events

  • 01 Feb 2017 Pantarhei completes a phase I trial in Prostate cancer (In volunteers) in Netherlands (Sublingual) (NCT02718378)
  • 31 Jan 2017 Phase-I clinical trials in Pregnancy (Prevention, In volunteers) in Bulgaria (PO) (NCT03075956)
  • 14 Apr 2016 Phase-II clinical trials in Vasomotor symptoms in Poland (PO, Capsule) (EudraCT2015-004018-44)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top